

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY DOCKET NO. D-2929CON		SERIAL NO. 09/845,514	
				Aoki et al. FILING 4/30/01 GROUP 1645			

RECEIVED

AUG 07 2001

TECH CENTER 1800/2900

AUG 02 2001

O I P E J C T 18

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	1	2,373,454	4/45	Bumny et al.	167	78	
	2	3,132,995	5/64	Berger et al.	167	78	
	3	4,713,240	12/87	Wilkins et al.	424	92	
	4	4,932,936	6/90	Dykstra et al.	604	51	
	5	5,055,291	10/91	Lam et al.	424	85.91	
	6	5,055,302	10/91	Laties et al.	424	427	
	7	5,053,005	10/91	Borodic	604	51	
	8	5,183,462	2/93	Borodic	604	51	
	9	2,719,102	9/55	Baldwin	167	78	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	10	WO 93/05800	4/93	PCT			
	11	WO 94/00481	1/94	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	12	Microbiological Review, Vol. 56, no. 1, March 1992, Wash. D.C. pp. 80-99					
	13	Journal of Neurology, Vol. 239, No. 1, January 1992, Berlin, pp. 16-20					
EXAMINER				DATE CONSIDERED 12/15/01			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 02 2001

AUG 07 2001

TECH CENTER 1600/2900

Docket Number (Optional)

D-2929CON

Application Number

09/845,514

Applicant(s)

Aoki et al.

Filing Date

4/30/01

Group Art Unit

1645

*EXAMINER

INITIAL

PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

"Therapeutic Uses of Botulinum Toxin", Jankovic, The New England Journal of Medicine, Vol. No. 17, April 1991, Boston, pp. 1186-1194

14

15

"Traitement Des Spasmes Faliaux Par La Toxine Botulique A". J. Fruphtalmul 1990, p. 135-259, Adams

16

"Bacterial Sources of Clostridical Neurotoxins" Chapter I, Botulinum Neurotoxin and Tetanis Toxin, Hatheway

17

"Paralytic Strabismus: The Rule of Botulinum Toxin". Elston et al., British Journal Ophthalmoly 69:891-1980

18

"Botulinum A Toxin for Cranial-Cervical Dystonia", Jankovic et al., Neurology 37: 616,1987

19

"Thyroid Eye Disease", Watson, Eye, Vol. 4 part 4

20

"Localized Injections of Botulinum Toxin for the Treatment..." Adv. In Neurology, Vol 50, 1989

21

"Electromyographic Findings in Focal Laryngeal...", Ann Otol Rhenal Laryngal 94:1, Blitzter et al.

22

Neurology 37 (suppl) 123 March 1987

23

"Cultural and Physiological Characteristics of Clostridium botulinum Type G and the Susceptibility of Certain Animals to its Toxin", Ciccarelli et al. Applied and Environmental Microbiology, Dec. 1977, p. 843-848

24

"Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine", Schantz et al., Microbiological Reviews, March 1992, p. 80-99

EXAMINER

DATE CONSIDERED

12/15/01

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.